Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sergey A. Grishin
Observed names:
S A Grishin,
S. A. Grishin,
S. Grishin,
S.A. Grishin,
Sergey Grishin
Institution:
R-Pharm (Russia)
Observed institutions:
Federal Almazov North-West Medical Research Centre,
Metroplex Clinical Research Center,
R-Pharm (Russia),
Medical University of Vienna,
The University of Texas Southwestern Medical Center
ORCID:
0000-0001-7299-660X
Observed ORCID:
0000-0001-7299-660X
OpenAlex ID:
A5101700390
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis
2022
·
Josef S. Smolen
, Eugen Feist
, et al.
·
New England Journal of Medicine
·
88
PDF
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
2022
·
Eugen Feist
, Saeed Fatenejad
, et al.
·
Annals of the Rheumatic Diseases
·
49
PDF
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
2024
·
Eugen Feist
, Roy M Fleischmann
, et al.
·
Annals of the Rheumatic Diseases
·
19
PDF
Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study
2024
·
Antonio Abbate
, Benjamin Van Tassell
, et al.
·
Journal of Cardiovascular Pharmacology
·
16
P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study
2021
·
Eugen Feist
, Saima Chohan
, et al.
·
Rheumatology
·
6
Inflammation‐mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis
2024
·
Svetlana Agachi
, Marina Beloukhova
, et al.
·
British Journal of Clinical Pharmacology
·
5
PDF
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
2024
·
Eugen Feist
, Roy M. Fleischmann
, et al.
·
Modern Rheumatology Journal
·
3
PDF
Op0045 Treatment of Idiopathic Recurrent Pericarditis With Goflikicept - First Data From the Interim Analysis of Phase 2/3 Ongoing Study
2022
·
A. Maslyanskiy
, V. Myachikova
, et al.
·
Annals of the Rheumatic Diseases
·
3
PDF
[Pilot clinical trial of ladasten].
2006
·
S A Siuniakov
, S A Grishin
, et al.
·
PubMed
·
3
P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy
2021
·
Eugen Feist
, Saeed Fatenejad
, et al.
·
Rheumatology
·
2
[Characteristics of ladasten effect in neurasthenia patients with various EEG parameters].
2008
·
G G Neznamov
, V K Bochkarev
, et al.
·
PubMed
·
2
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial
2025
·
Eugen Feist
, Michael E. Luggen
, et al.
·
Arthritis Research & Therapy
·
1
PDF
Abstract 4340531: Interleukin-1 Blockade in Patients With ST-Segment-Elevation Myocardial Infarction: a Pooled Analysis of Randomized Clinical Trials of Anakinra and Goflikicept
2025
·
Michele Golino
, Michele Marchetta
, et al.
·
Circulation
·
1
Results of a 24-week open-label phase II study of olokizumab in adolescent patients with polyarticular juvenile idiopathic arthritis
2024
·
E.I. Alexeeva
, T.M. Dvoryakovskaya
, et al.
·
Voprosy praktičeskoj pediatrii
·
1
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
2023
·
E. Feist
, S. Fatenejad
, et al.
·
Modern Rheumatology Journal
·
1
PDF
Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
2022
·
E. V. Shipaeva
, O. V. Filon
, et al.
·
Biological Products Prevention Diagnosis Treatment
·
1
PDF
Pos0645 Long-term Safety and Efficacy of Olokizumab in Patients With Rheumatoid Arthritis – Result of an Open-label Extension Study, Credo4
2022
·
E. Feist
, E. Nasonov
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
2026
·
Roy M. Fleischmann
, Vibeke Strand
, et al.
·
Rheumatology and Therapy
PDF
Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period
2025
·
Ekaterina I. Alexeeva
, Tatiana M. Dvoryakovskaya
, et al.
·
Pharmaceuticals
PDF
Gene Expression Analysis and Biomarkers of Inflammation During Goflikicept Therapy for Idiopathic Recurrent Pericarditis: Phase Ii/iii Study Results
2024
·
Valentina Myachikova
, Alexey Maslyanskiy
, et al.
·
Journal of the American College of Cardiology
Pos1071 the Impact of Comorbidities on the Efficacy of Il-6 Inhibitor Olokizumab Compared to Adalimumab
2023
·
E. Feist
, M.E. Luggen
, et al.
·
Annals of the Rheumatic Diseases
PDF
371O First in human study of RPH-203, a new potent RANKL blocker, for the treatment of bone metastasis
2015
·
S. Archuadze
, S. Grishin
, et al.
·
Annals of Oncology
PDF
P.3.037 Results of clinical study of ladasten, a drug with stimulatory and anxiolytic activity
2005
·
S.A. Syunyakov
, S.A. Grishin
·
European Neuropsychopharmacology
Show more works
View as search
Works count:
23
Citation count:
202
H-index:
5
I10-index:
4
Year
Topic
Type
